Zhao Xu

Discovery of a promising agent IQZ23 for the treatment of obesity and related metabolic disorders.

Ji-Ming Ye, Yong Rao, Chan Li, 2020, European journal of medicinal chemistry.

Natural alkaloid bouchardatine ameliorates metabolic disorders in high‐fat diet‐fed mice by stimulating the sirtuin 1/liver kinase B‐1/AMPK axis

Yong Rao, Zhishu Huang, L. Gu, 2017, British journal of pharmacology.

Bouchardatine analogue alleviates non‐alcoholic hepatic fatty liver disease/non‐alcoholic steatohepatitis in high‐fat fed mice by inhibiting ATP synthase activity

Yong Rao, Chan Li, Yao-Hao Xu, 2019, British journal of pharmacology.

Bouchardatine analogue alleviates NAFLD/NASH in high fat fed mice via blunting ATP synthase activity.

Yong Rao, Chan Li, Yao-Hao Xu, 2019, British journal of pharmacology.

Design, synthesis and biological evaluation of novel bouchardatine analogs as potential inhibitors of adipogenesis/lipogenesis in 3T3-L1 adipocytes.

Yong Rao, Yao-Hao Xu, Yu-Tao Hu, 2018, European journal of medicinal chemistry.